ERBB2 and head and neck squamous cell carcinoma: In addition, three clinical trials, NCT05117138, NCT03740256, and NCT05239143, will evaluate the safety and efficacy of AMT-116 CAR-T cells, HER2 chimeric antigen receptor-specific cytotoxic T lymphocytes (HER2-specific CAR T cells), and P-MUC1C-ALLO1 CAR-T cells, respectively, in the treatment of HNSCC.